Hormonal contraception and the risks of STI acquisition: results of a feasibility study to plan a future randomized trial.
BACKGROUND
Because of limitations in observational studies, a randomized controlled trial (RCT) would help clarify whether hormonal contraception increases the risks of acquiring a sexually transmitted infection (STI). However, the feasibility of such a trial is uncertain.


METHODS
We conducted a study to assess the feasibility of conducting a RCT that would compare the acquisition risk for Chlamydia trachomatis and Neisseria gonorrhoeae in women randomized to an intrauterine device (IUD) or depot medroxyprogesterone acetate (DMPA). In our cross-sectional survey conducted at three clinics, we gave information on a potential RCT to clients, asked them questions to assess comprehensibility and finally asked respondents whether they would consider enrolling in such a trial. In addition, the 190 participants provided urine or endocervical swab specimens so we could estimate the prevalence of STIs.


RESULTS
Overall, 70% of participants stated that they would take part in a future trial and accept randomization to either the IUD or DMPA. Participant understanding of the trial requirements was high. Twenty-nine percent of the participants were infected with either N. gonorrhoeae or C. trachomatis.


CONCLUSIONS
With a high prevalence of STI in this population and the apparent willingness of appropriate candidates to participate, an RCT to measure risks of incident STI infection from hormonal contraception appears feasible.
Hubacher
David
D
Family Health International, Research Triangle Park, NC 27709, USA. dhubacher@fhi.org
Raymond
Elizabeth R
ER
Beksinska
Mags
M
Delany-Moretlwe
Sinead
S
Smit
Jenni
J
Hylton-Kong
Tina
T
Moench
Thomas R
TR
D002690:Chlamydia Infections / Q000209:etiology / Q000517:prevention & control; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D003430:Cross-Sectional Studies; D005240:Feasibility Studies; D005260:Female; D006069:Gonorrhea / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007434:Intrauterine Devices / Q000009:adverse effects; D008525:Medroxyprogesterone / Q000009:adverse effects; D009344:Neisseria gonorrhoeae / Q000302:isolation & purification; D012307:Risk Factors; D012725:Sexual Behavior; D015231:Sexually Transmitted Diseases, Bacterial / Q000209:etiology / Q000517:prevention & control*
D003278:Contraceptives, Oral, Hormonal; D008525:Medroxyprogesterone